Summary
The progress of an epidemic in a small closed community is simulated by an agent-based model which allows vaccination and variation. The attributes of the virus are governed by two genetic loci: the P-locus, which determines growth, and the M-locus, which determines immune characteristics. Mutation at either locus modifies the attributes of the virus and leads to evolution through natural selection. For both loci the crucial variable is the potential mutation supply UPot, because evolution is likely to happen when UPot > 1. Mutation at the P-locus causes a limited increase in virulence, which may be affected by vaccine design. Mutation at the M-locus may cause a qualitative shift of dynamic regime from a simple limited epidemic to a perennial endemic disease by giving rise to escape mutants which may themselves mutate. A broad vaccine that remains efficacious despite several mutations at the M-locus prevents this shift and provides protection despite the evolution of the virus. Escape variants may nevertheless arise through recombination after coinfection, and can be suppressed by timely revaccination, using the prevalent strain to design the vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
My research is supported by a Discovery Grant from the Natural Sciences and Engineering Research Board of Canada (Grant RGPIN/6945-2013).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was conducted within the usual McGill University protocols. No specific approval process is necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos